For many investors, genomics as a field is nothing new, albeit still exciting. But there's a new type of revolutionary science on the horizon, and a life sciences company called Seer (NASDAQ: SEER) that IPO'd in December thinks it holds the key to unlock this new frontier.
In this Motley Fool Live video recorded on May 7 , healthcare and cannabis bureau chief Corinne Cardina and Seer's CEO Dr. Omid Farokhzad talk about what healthcare investors need to know about the cutting-edge world of proteomics.
For further details see:
CEO of Newly IPO'd Seer: For Biotech Investors, Proteins Are The New DNA